Fingolimod

Drug Profile

Fingolimod

Alternative Names: Fingolimod hydrochloride; FTY-720; Gilenia; Gilenya; Imusera; TDI-132

Latest Information Update: 01 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Pharma Corporation; Taito
  • Developer ALS Therapy Development Institute; Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Novartis
  • Class Ethanolamines; Propylene glycols; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunosuppressants; Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Graft-versus-host disease; Myocarditis; Optic neuritis; Renal transplant rejection; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 27 Jun 2017 CTP Push 229220 - Study already discontinued. Just added minor details to KDM and modified the HE to reflect termination
  • 25 Apr 2017 The Independent Data Monitoring Committee recommends to terminate a phase-III clinical trial in Chronic inflammatory demyelinating polyradiculoneuropathy
  • 22 Apr 2017 Novartis Pharmaceuticals terminates a phase-III clinical trial in Chronic inflammatory demyelinating polyradiculoneuropathy in Australia, USA, United Kingdom, Belgium, France, Germany, Greece, Italy, Netherlands, Poland, Spain, Norway, Czech Republic, Canada, Israel and Japan upon the recommendation of the IDMC (PO) (NCT01625182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top